Novel antiplatelet therapies following percutaneous coronary interventions

Current Opinion in Investigational Drugs

Volumn 10, Issue 9, 2009, Pages 902-911

  Ahrens, I ^a,b   Bode, C ^b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Acute coronary syndrome; Antiplatelet therapy; P2Y12 receptor; PAR1 antagonist; Percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; ARC 1779; CANGRELOR; CILOSTAZOL; CLOPIDOGREL; DG 041; DIPYRIDAMOLE; E 5555; ELINOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCOPROTEIN P INHIBITOR; HIRULOG; INS 50589; PACLITAXEL; PLACEBO; PRASUGREL; PRT 060128; PRT 128; RAPAMYCIN; REGRELOR; SARPOGRELATE; SCH 530348; TERUTROBAN; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ADJUVANT THERAPY; ARTERY DISEASE; BARE METAL STENT; BLEEDING; CLINICAL PROTOCOL; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG DELIVERY SYSTEM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELUTING STENT; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DYSPNEA; HEART DISEASE; HEART INFARCTION; HUMAN; IMPLANTATION; INTERMITTENT CLAUDICATION; LOADING DRUG DOSE; LONG TERM CARE; LOW DRUG DOSE; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; REVIEW; SINGLE DRUG DOSE; ST SEGMENT ELEVATION; STABLE ANGINA PECTORIS; STENT THROMBOSIS; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COATED MATERIALS, BIOCOMPATIBLE; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; HUMANS;

EID: 69649089173     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (54)

1. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO, Feldman TE, Kern MJ, O'Neill WW, Schaff HV, Whitlow PL et al: 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines: 2007 writing group to review new evidence and update the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention, writing on behalf of the 2005 writing committee. Circulation (2008) 117(2):261-295.
2. Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Fox KA, Granger CB, Jolly S, Rupprecht HJ, Widimsky P, Yusuf S: Design and rationale of CURRENT-OASIS 7: A randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Am Heart J (2008) 156(6):1080-1088.e1.
3. Airoldi F, Colombo A, Morici N, Latib A, Cosgrave J, Buellesfeld L, Bonizzoni E, Carlino M, Gerckens U, Godino C, Melzi G et al: Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation (2007) 116(7):745-754. (Pubitemid 47255992)
4. Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K, Yasumoto H, Nishikawa H, Hiasa Y, Muramatsu T, Meguro T, Inoue N et al: Antiplatelet therapy and stent thrombosis after sirolimuseluting stent implantation. Circulation (2009) 119(7):987-995. • Large observational study to determine the optimal length of dual antiplatelet therapy after PCI with the implantation of drug eluting stents.
5. Ahrens I, Peter K, Bode C: Use of GPIIb/IIIa inhibitors in cardiovascular medicine. Expert Rev Cardiovasc Ther (2003) 1(2):233-242. • Comprehensive review on drugs that block the platelet fibrinogen receptor GP IIb/IIIa.
6. Pollack CV Jr, Braunwald E: 2007 update to the ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: Implications for emergency department practice. Ann Emerg Med (2008) 51(5):591-606.
7. Mehilli J: Pretreatment with a high loading dose of clopidogrel and value of abciximab during primary coronary intervention in patients with acute MI: Results of the randomized BRAVE-3 trial. 57th Annual Scientific Session of the American College of Cardiology, Chicago, IL, USA (2008) 57:Abs 2404-2414
8. White HD, Ohman EM, Lincoff AM, Bertrand ME, Colombo A, McLaurin BT, Cox DA, Pocock SJ, Ware JA, Manoukian SV, Lansky AJ et al: Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol (2008) 52(10):807-814.
9. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G et al: Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med (2008) 358(21):2218-2230. (Pubitemid 351724451)
10. Fox KA, Steg PG, Eagle KA, Goodman SG, Anderson FA Jr, Granger CB, Flather MD, Budaj A, Quill A, Gore JM: Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. J Am Med Assoc (2007) 297(17):1892-1900.
11. Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A, Golanski J, Sitkiewicz D, Pregowski J, Gorski J, Zembala M et al: Interindividual variability in the response to oral antiplatelet drugs: A position paper of the Working Group on Antiplatelet Drugs Resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J (2009) 30(4):426-435. • Comprehensive review on the clinically important observation of a variable response to antiplatelet agents, commonly referred to as either aspirin or clopidogrel resistance.
12. Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, Moschi G, Gori AM, Abbate R, Antoniucci D: Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol (2007) 49(24):2312-2317. (Pubitemid 46891710)
13. Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, Ernst A, Sawhney NS, Schatz RA, Teirstein PS: Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J (2008) 29(8):992-1000. (Pubitemid 351844676)
14. Gachet C: P2 receptors, platelet function and pharmacological implications. Thromb Haemost (2008) 99(3):466-472. • An up-to-date overview of the current knowledge of purinergic P2 receptors on platelets.
15. Wiviott SD, Trenk D, Frelinger AL, O'Donoghue M, Neumann FJ, Michelson AD, Angiolillo DJ, Hod H, Montalescot G, Miller DL, Jakubowski JA et al: Prasugrel compared with high loadingand maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation (2007) 116(25):2923-2932. (Pubitemid 350291199)
16. 12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J (2008) 29(1):21-30.
17. Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS 2nd, Brandt JT, Darstein C, Jakubowski JA, Salazar DE: Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther (2007) 81(5):735-741.
18. 12 antagonist, with clopidogrel in percutaneous coronary intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation (2005) 111(25):3366-3373.
19. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J et al: Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2007) 357(20):2001-2015. • Original publication of the efficacy trial that led to the approval of prasugrel. (Pubitemid 350106708)
20. FDA: FDA approves Effient to reduce the risk of heart attack in angioplasty patients. Press Release (2009): July 10
21. Reuters: EMEA grants marketing authorisation for prasugrel (Efiant). Press Release (2009): February 24
22. 12 antagonist AZD6140 with aspirin in patients with atherosclerosis: A double-blind comparison to clopidogrel with aspirin. Eur Heart J (2006) 27(9):1038-1047.
23. Cannon CP, Husted S, Harrington RA, Scirica BM, Emanuelsson H, Peters G, Storey RF: Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: Primary results of the DISPERSE-2 trial. J Am Coll Cardiol (2007) 50(19):1844-1851. (Pubitemid 350007959)
24. AstraZeneca plc: AstraZeneca announces top line results from pivotal phase III study for Brilint. Press Release (2009): May 11.
25. 12 antagonist, antiplatelet agent. Drugs Future (2008) 33(2):101.
26. 12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: Results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am Heart J (2006) 151(3):689.e1-689.e10.
27. Dovlatova NL, Jakubowski JA, Sugidachi A, Heptinstall S: The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J Thromb Haemost (2008) 6(7):1153-1159. (Pubitemid 351859125)
28. Steinhubl SR, Oh JJ, Oestreich JH, Ferraris S, Charnigo R, Akers WS: Transitioning patients from cangrelor to clopidogrel: Pharmacodynamic evidence of a competitive effect. Thromb Res (2008) 121(4):527-534. (Pubitemid 351174272)
29. The Medicines Company: The Medicines Company discontinues phase III CHAMPION clinical trial program for cangrelor. Press Release (2009): May 13.
30. 12 ADP-receptor antagonist, INS50589. Platelets (2007) 18(5):346-356.
31. Inspire Pharmaceuticals Inc: Inspire terminates phase 2 clinical trial for platelet aggregation inhibitor. Press Release (2006): Aug 07.
32. 12 inhibitor for iv and oral use. J Am Coll Cardiol (2007) 49(9 Suppl A):326A.
33. 12 antagonist overcomes high platelet reactivity in patients non-responsive to clopidogrel therapy. Circulation (2008) 118(18 Suppl):Abs 5603.
34. Zhang W, Colman RW: Thrombin regulates intracellular cyclic AMP concentration in human platelets through phosphorylation/ activation of phosphodiesterase 3A. Blood (2007) 110(5): 1475-1482. (Pubitemid 47443962)
35. Chackalamannil S, Wang Y, Greenlee WJ, Hu Z, Xia Y, Ahn HS, Boykow G, Hsieh Y, Palamanda J, Agans-Fantuzzi J, Kurowski S et al: Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem (2008) 51(11):3061-3064. (Pubitemid 351821864)
36. Moliterno DJ, Becker RC, Jennings LK, Berman G, Yang B, Strony J, Veltri E, Harrington RA: Results of a multinational randomized, double-blind, placebo-controlled study of a novel thrombin receptor antagonist (SCH 530348) in percutaneous coronary intervention. American College of Cardiology 56th Annual Scientific Session, New Orleans, LA, USA (2007).
37. Becker RC, Moliterno DJ, Jennings LK, Pieper KS, Pei J, Niederman A, Ziada KM, Berman G, Strony J, Joseph D, Mahaffey KW et al: Safety and tolerability of SCH 530348 in patients undergoing nonurgent percutaneous coronary intervention: A randomised, double-blind, placebo-controlled phase II study. Lancet (2009) 373(9667):919-928. • Reports results from a recent double-blind, randomized clinical trial conducted with a selective PAR1 antagonist in patients undergoing PCI.
38. Ahrens I, Bode C, Peter K: Inhibition of platelet activation and aggregation. Handbook Exp Pharmacol (2005) 170:443-462.
39. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A: Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): Randomised controlled trial. Lancet (2006) 367(9523):1665-1673.
40. Biondi-Zoccai GG, Lotrionte M, Anselmino M, Moretti C, Agostoni P, Testa L, Abbate A, Cosgrave J, Laudito A, Trevi GP, Sheiban I: Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention. Am Heart J (2008) 155(6):1081-1089.
41. Shinohara Y, Nishimaru K, Sawada T, Terashi A, Handa S, Hirai S, Hayashi K, Tohgi H, Fukuuchi Y, Uchiyama S, Yamaguchi T et al: Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial. Stroke (2008) 39(6):1827-1833.
42. Inpharma Weekly: Sarpogrelate improves ischaemic injury by inhibiting ST-segment elevation during percutaneous coronary intervention. Press Release (2004): February 28.
43. Kawano J, Tamura A, Naono S, Kohtoku M, Zaizen H, Yano S, Kadota J: Usefulness of sarpogrelate in sirolimus-eluting coronary stenting Circulation Journal (2006) 70( Suppl 1):PJ-670.
44. Chan MY, Cohen MG, Dyke CK, Myles SK, Aberle LG, Lin M, Walder J, Steinhubl SR, Gilchrist IC, Kleiman NS, Vorchheimer DA et al: Phase 1b randomized study of antidote-controlled modulation of Factor IXa activity in patients with stable coronary artery disease. Circulation (2008) 117(22):2865-2874. (Pubitemid 351787073)
45. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, Horvath CJ, Merlino PG, Marsh HN, Healy JM, Boufakhreddine S, Holohan TV, Schaub RG: First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation (2007) 116(23):2678-2686. (Pubitemid 350291240)
46. Paulinska P, Jilma B, Firbas C, Schaub RG, Gilbert JC, Knoebl P: The anti von Willebrand factor aptamer ARC1779 prevents the desmopressin-induced thrombocytopenia in VWD type 2B. ASH Annual Meeting Abstracts (2008) 112(11):Abs 3374.
47. Tay KH, Lane DA, Lip GY: Bleeding risks with combination of oral anticoagulation plus antiplatelet therapy: Is clopidogrel any safer than aspirin when combined with warfarin? Thromb Haemost (2008) 100(6):955-957.
48. Shantsila E, Lip GY: Apixaban, an oral, direct inhibitor of activated Factor Xa. Curr Opin Investig Drugs (2008) 9(9):1020-1033.
49. Gibson CM, Mega JL, Hammett CJ, Hricak V, Bordes P, Witkowski A, Markov V, Burton P, Braunwald E: 2008 Late-breaking clinical trial abstracts. Circulation (2008) 118(22):2309-2317.
50. Brisol-Myers Squibb Co: New data is presented on investigational oral anticoagulant apixaban in acute coronary syndrome patients. Press Release (2008): September 02.
51. Johnson & Johnson: Rivaroxaban phase II dose-ranging study demonstrates encouraging response rates in treatment of acute coronary syndrome patients. Press Release (2008): November 10.
52. Biondi-Zoccai GG, Lotrionte M, Agostoni P, Abbate A, Fusaro M, Burzotta F, Testa L, Sheiban I, Sangiorgi G: A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease. Eur Heart J (2006) 27(22):2667-2674. (Pubitemid 44729867)
53. International Standard Randomised Controlled Trial Number Register: Current Controlled Trials Ltd, London, UK (2009) www. controlled-trials.com/ ISRCTN66157730/66157730
54. deCODE genetics Inc Product Pipeline: deCODE genetics Inc, Reykjavik, Iceland (2009) www.decode.com/Pipeline/Index.php